Your immune system triggers inflammation to fight the virus, which can often lead to a decreased appetite, fatigue, and muscle aches
However, GLP-1 receptor occupancy and downstream signaling may persist even as plasma levels drop, creating a lag between apparent drug 'wear-off' and loss of appetite suppression or glucose control
A Health inequities related to diabetes and its complications are well documented and have been associated with greater risk for diabetes, higher population prevalence, and poorer diabetes outcomes
The FDA has approved Eli Lillys oral GLP-1, Foundayo (orforglipron), the company announced April 1
Know the Prognosis: The report indicates that symptoms may resolve spontaneously after several weeks or, more definitively, upon discontinuation of the drug